Company intelligence / Profile preview

AUSTRAL Dx

Ownership: Private
Development stage: Preclinical

Overview

AUSTRAL Dx has developed the Surface Motion Camera, a novel medical device that uses airborne ultrasound to non-invasively assess cardiac and pulmonary health within three minutes. The prototype has shown promising preliminary results in hospital-based studies for rapid screening and triage of patients with symptoms such as dyspnea or chest pain. The company’s first proof-of-concept clinical trial was ongoing as of early 2024. Commercialization will require finalizing the prototype, completing trials, obtaining ISO13485 certification, and achieving adoption by emergency departments[1][2].

Therapeutic areas: PulmonologyCardiovascular
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Caen Normandie University Hospital — academic/hospital partner for initial clinical study/trial

Beyond the preview

Go deeper on AUSTRAL Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUSTRAL Dx.

Explore the full profile